The brief

Analyst view

• AI + automated chemistry for drug discovery. Founded 2019 by computational chemists Tom Miller and Fred Manby; raised $461.8M.
• IAM1363: oral, brain-penetrating HER2 inhibitor. Phase 1/1b for HER2+ solid tumors.
• IPO filed Sep 2026 for Nasdaq (ticker IAM). Registrational trials planned 2027.

Technical approach

As reported

AI-Driven Discovery

Machine learning for molecular design

Iambic uses machine learning models trained on chemistry data to predict which molecular structures will be potent, selective, and safe before synthesis.

Automated Chemistry

Robotic synthesis and testing

Automated chemistry platforms rapidly synthesize and test hundreds or thousands of candidate molecules, condensing years of synthesis work into weeks.

Biology Integration

High-throughput biology assays

Automated cell-based and biochemical assays rapidly assess potency, selectivity, and toxicity of candidates, feeding data back to the AI models.

Platform Approach

Reusable discovery engine

The platform is disease-agnostic; once validated on IAM1363, it can be deployed to discover drugs for other targets and tumor types.

Show all 4